2011

Oktober

• Transics International: Creafund II  (Stille Maatschap Transics shares) past the 10 % with 878.629 Transics shares.

April

• Transics International: Creafund II  past the 5 % with 416.876 Transics shares.

 

2010

October

•  Transics International. Creafund II bought  a package of 110.037 Transics International shares

 June

 

March

 

 

• March 9, 2010. IBt Bebig announced today that, because of recent developments, the acceptance period for the takeover bid on all IBt securities by Eckert & Ziegler AG and SMI Steglitz Medinvest has been extended to 4:00 p.m., March 17, 2010. Press release.

 

 

• February 23, 2010. IBt Bebig group announced today that the offering period of the takeover bid by Eckert & Ziegler AG and SMI Steglitz Medinvest for all IBt shares starts today and will run until March 9, 2010 inclusive. Press release.

January

• January 21, 2010. Trading Update - Year 2009. Press release.
  
  Record Results
  Very robust growth and Strong profitability in FY2009
  
  - Sales EUR 32.5 million
  - EBITDA to be close to EUR 8 million
  - Net Profit to exceed EUR 4.8 million

 

• January 20. BRUSSELS COURT OF APPEAL ORDERS ECKERT & ZIEGLER TO MAKE TAKEOVER BID FOR 100 PERCENT OWNERSHIP OF IBT
  
  IBt Bebig (Reuters: IBTH.BR – Bloomberg: IBTB BB) has been informed of the decision of the Eighteenth Division of the Brussels Court of Appeal on the appeals filed by Eckert & Ziegler AG (EZAG) and SMI Steligtz (SMI) of decisions in favor of IBt Bebig minority shareholder Creafund II and Belgian securities regulator CBFA.
  
  The appeals court judgment, which covers the three cases pending, can be summarized as follows:
  
  - The court has confirmed the CBFA orders of April 28 and May 27, 2009 stating that EZAG and SMI should be deemed "persons acting in concert" and that, because their ownership of IBt common stock exceeded 30 percent as of January 26, 2009, they are required to make a joint and several takeover offer.
  
  - The court has sided with Creafund II in its suit to compel EZAG and SMI to launch a mandatory takeover bid and to pay damages.
  
  -The court has ordered EZAG and SMI to pay damages and legal costs.
  
  The court points out that, the suits have become largely meaningless in practice, since a takeover offer has been initiated. The full text of the Brussels Court of Appeals decision, issued on January 19, 2010, will be available on the IBt website this morning:
  http://www.ibt-bebig.eu/en/sidenavigation/press/press_releases.html
  

2009

December  

•  December 28, 2009. Eckert & Ziegler Strahlen- und Medizintechnik have submitted today an application file with the Belgian financial authority CBFA for a public take-over bid in cash for all outstanding 10.96 mm shares of EURONEXT listed medical device producer International Brachytherapy SA (IBt). The bid, jointly submitted with fellow IBt shareholder Steglitz MedInvest UG (SMI), offers 3.64 EUR per share, and hence has a maximum volume, at full acceptance, of about 40 mm EUR. The prospectus and the memorandum in response for the bid will be published after approval by the CBFA, which is expected to occur by the end of January 2010. With the take-over bid, Eckert & Ziegler and SMI aim at ending the ongoing litigation around IBt 
  that  now has lasted for almost twelve months. In order to facilitate a quick conclusion to all deadlocks, Eckert & Ziegler and SMI decided to proceed with a voluntary performance of the injunction that the Belgian financial authority CBFA had issued on 28 April 2009 and 27 May 2009, ordering both Eckert & Ziegler and SMI to launch a mandatory public takeover bid on IBt at 3.47 per share. Further, Eckert & Ziegler and SMI have increased the initial asking price of 3.47 EUR per share by the applicable legal interest (5.5%) to a price of 3.64 EUR per share, so that their offer also satisfies all claims brought forward against Eckert & Ziegler and SMI in a separate lawsuit by IBt shareholder Creafund II SCA. Press release EZAG.

• December 2. IBt Bebig announced today that it has signed a Strategic Alliance agreement with Core Oncology, Inc., based in Santa Barbara, California. Press release.  

October        

• October 5. The IBt Bebig group has completed the installation of a Multisource® Co-60 HDR (High Dose Rate) afterloader equipment in the Vajira Hospital in Bangkok, Thaïland. Press release.

August

• August 31. Ibt : Financial Results, H1 - 2009 Regulated Information. Press release.
  
  Record Results
  Gross Margin 9.4 million EUR + 195 %
  EBITDA 4.2 million EUR + 154 %
  Net Profit 2.9 million EUR
  Guidance for FY 2009 revised upwards

July

• July 28. Ibt: Trading update – Half year 2009. Press release.
  
  Very strong growth trend and record results during H1,09
  Revenues to exceed 16 millions EUR
  Gross Margin to reach 9 millions EUR
  EBIT to be close to 3.2 millions EUR

May

• May 12. Ibt: Q1, 2009 – Trading Update . Press release.
  
  Record Results and Growth achieved during Q1, 2009  
  
  Sales of products 6.9 million EUR + 149 %
  Gross Margin 4.1 million EUR + 240 %
  EBITDA 1.6 million EUR + 136 %
  Net Profit 1.0 million EUR + 804 %
  Outlook for 2009 revised

April

• April 28. IBt has been notified by the Belgian regulatory authority, the CBFA, of its decision, in accordance with European legislation, to impose on two of its shareholders (Eckert & Ziegler AG and SMI Stegliz Medinvest) to launch a mandatory take over bid on all IBt shares, type ‘B’ beneficiary shares and on all outstanding IBt “D warrants”.
  
  The imposed price for the regular shares is 3.47 EUR/share. The price is to be paid either in cash or in shares of Eckert & Ziegler AG, or a combination thereof.
  
  The period of the offer will start no later than 40 working days from this day (unless Eckert & Ziegler AG and/or SMI Steglitz Medinvest appeal against the CBFA decision)(28/4).
• April 8. IBt announces the successful conclusion of the negotiations on the creation of a Russian joint venture. The agreement related to the formation of "NanoBrachyTech", a Russian company based in Moscow, was signed today by the three parties involved.
  
  The new company will focus on innovative technologies for the treatment of cancer by brachytherapy in the Russian Federation. The first projects of the joint venture will encompass (1) the acquisition and/or development of the technologies related to radioactive nanosources, and (2) the launch of an R&D program related to the usage of brachytherapy for the treatment of liver cancer (8/4).

March

• March 20. Ibt: Annual Results – 2008. Press release.
  
  Turnover EUR 17.2 million + 115 %
  EBITDA EUR 3.8 million + 567 %
  Net result (before restructuring costs) EUR 1.1 million
  Outlook 2009 - strong sales increase expected + 50 % 
• March 19. IBt - (Reuters: IBTH.BR - Bloomberg: IBTB BB) announces that it has filed an indemnification claim procedure against Eckert & Ziegler AG ("EZAG") for the breach of some of the representations and warranties made by EZAG under the terms of the agreement signed between IBt and EZAG in Feb08. EZAG has initiated a similar procedure against IBt.
  
  The next step of this procedure provides that both parties now seek to find a settlement of their claims. This process is currently well under way and will ensue, if succesfull, in no impact on the results of the company.

February

• February 16. Creafund II has introduced a claim before the Court of Appeal of Brussels whereby it alleges that Eckert & Ziegler Strahlen- und Medizintechnik AG ("EZAG") (holder of 29.9% of voting rights) should be required to launch a mandatory public takeover bid at a price per IBt share of 3.47 euros, pursuant to Article 5 of the law of 01 April 2007 on takeover bids, as Creafund considers that EZAG acts in concert with SMI Steglitz (22% of voting rights).

2008

October 

• October 14. IBt and Eckert & Ziegler have reached an agreement whereby IBt will purchase two business segments currently operated by subsidiaries of EZAG:
  
  1. Treatment of Eye Cancer (Implants Plaques)
  2. Treatment of Gynecological Cancers (Temporary Implants) 
  
  Press release.

September

• Through an LMBO operation, Creafund II acquires a majority interest in Distrac NV in Hoegaarden, a wellcare products distributor. Distrac is the exclusive distributor of and provides (technical) services in the Be(ne)lux countries for a broad spectrum of products for hospitals, homes of rest and homes for the elderly, national health services, medical specialist shops and pharmacies. This spectrum includes orthopaedic materials, mattresses and pillows (Tempur®), beds and related furniture (Stiegelmeyer/Burmeier) as well as mobile seats and chairs (Ravello).
  
  The company was established at the end of 1992 by Johan Struyf and with 18 employees, the company is growing at a rate of 20% a year up to €11 million in 2007.
  
  The operational day-to-day management remains in the hands of Kris Struyf (who has strengthened his shareholder status) and Johan Struyf. Joh. Stiegelmeyer & Co GmbH, an important German manufacturer of hospital beds and furniture with a turnover of more than €80 million, also remains represented in the shareholders.
  
  By taking Creafund II on board, Distrac wishes to ensure its future expansion. Because of the increasing greying of the population, a substantial growth can be expected in the sector in which Distrac is active. This also means that there is an important perspective on consolidation in this sector. As total package provider, Distrac wants to play a role, apart from internal growth, in looking at all possibilities to keep expanding its spectrum and market share with a focus on the medical sector.

August

• In Q3/2008, the Luxauto group was acquired for 100% by EJ Holding NV after a study into horizontal and vertical integration through acquisitions. The company hires out cars, vans and trucks on short and medium term through 16 establishments in Belgium.

July

•  IBt’s manufacturing has moved to Berlin (Bebig/Ezag) completely since 1/7/08. The reorganisation in Seneffe is completed. Only the CEO, Sales & Marketing and Finance are left; manufacturing and R&D departments are located in Berlin. On 11/11, the afterloader department of EZAG was also acquired by IBt.

June

• June 2. Ibt: Reorganization of the activities of the IBt group. Press release
  
  This integration and reorganisation plan, if implemented, is intended to improve production efficiency at IBt and to achieve a better distribution of activities between the different group sites.
  
  The broad lines of this integration plan involve (1) concentrating at Seneffe the Sales and Marketing activities, plus R&D relating to the intellectual property held by IBt , and all the general parent company departments (Finance, HR, IR, legal, etc.) and (2), concentrating the implants production activities on the Berlin site.
  
  Out of a concern to respect all legislation in this matter, the company has therefore announced today its intention of closing the “Manufacturing” department of its Seneffe site and to proceed with a collective dismissal of workers. In accordance with the applicable procedures, senior management has proposed to the trade union organizations to initiate the information and consultation phase with a view to determining, on the one hand, the possibilities open in order to avoid or reduce the mass redundancies and, on the other hand, the social measures to be taken to attenuate the consequences of a collective dismissal.

April

• In April 2008, the decision was made to enter into two IIG funds: Nautilus and Ulitka. Nautilus invests in semi-industrial projects located in Eastern Europe. Ulitka invests in semi-industrial projects located in Russia. 2007

November 

• Through a change of Articles of Association, Creafund II transforms itself into an investment company (holding) with the aim of maintaining a long-term strategy in participations which lend themselves to it. This includes active participation in external growth opportunities.

2006

November

• Creafund II acquires Mercedes concessionaire Ghistelinck, with main office in Waregem. Ghistelinck has five concessions in East- and West-Flanders (Waregem, Courtrai, Oudenarde, Mouscron and Deinze) and is specialised in cars and buses, vans and trucks of this German brand. Last financial year, the group recorded a consolidated turnover of €100 million. It employs 200 people.
• Rudy Van Baelen, CEO of The Sniffers, a recent participation of Creafund II, has won the Unizo “SME entrepreneur of the year” award for 2006.

October 

• Through a Management Buy In (MBI), Creafund II acquires a substantial interest in the fast-growing company The Sniffers in Mol, established in 1994 by Rudy Van Baelen. The existing management also remains in place. The company is specialised in detecting, measuring and analysing the emission of (fugitive) gasses in the chemical and oil processing industry and pipeline integrity inspections on land.

July

• On 26/07/06, Creafund II took an interest of 55.07% in Exmore Technology in Beerse.

May

• Transics, a participation of Creafund II and manufacturer of board computers for trucks in Ypres, was sold to the American Investment Group Carlyle, a global company with an impressive list of prominent (ex) politicians and business people as advisors and/or shareholders (from the Bush family and George Soros to the Saudi royal family). With its almost 300 partners, this group manages around 39 funds for a total of approximately $40 billion. This operation was intended to give the company more leverage to become a Pan-European player, since on a fleet of 3.5 million trucks, only 150,000 have been equipped with board computers so far. The 2 founders-managers, Walter Mastelinck and Ludwig Lemenu remain on board with 20%, whereas all venture capitalists (Creafund, Rendex, ABN Amro, TrustCapital and Stroke Fund) have exited. This is Creafund’s biggest operation ever and its interest of more than 15% provides substantial added value with important IRR(>30%).